Drugs / davunetide
davunetide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01056965 | Jan 2010 → Dec 2012 | chromosome 17 disorder, corticobasal syndrome, progressive non-fluent aphasia, progressive supranuclear palsy +1 | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01110720 | Oct 2010 → Nov 2012 | progressive supranuclear palsy | Allon Therapeutics | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00422981 Comparator | Jan 2007 → Jan 2008 | subjective cognitive decline | Allon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00404014 Comparator | Aug 2006 → Jun 2008 | cognitive impairment with or without cerebellar ataxia | Allon Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | davunetide | “acute administration of intravenous davunetide (AL-208, ClinicalTrials.gov ID NCT00404014)” PMID 41173865 ↗ Oct 2025 |
| Known as | AL-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422981 ↗ |
| Known as | AL-208 | “acute administration of intravenous davunetide (AL-208, ClinicalTrials.gov ID NCT00404014)” PMID 41173865 ↗ Oct 2025 |
| Known as | Davunetida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103826 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2103826 ↗ |
| Route | Intravenous | “acute administration of intravenous davunetide” PMID 41173865 ↗ Oct 2025 |